Bullish & Foolish
Full TRAW fundamentals All 466 on the Survival Watch

TRAWTraws Pharma, Inc.

Is Traws Pharma struggling financially?

Yes, by its own account. Traws Pharma told the SEC on 29 May 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$8.1M
Source filing
DEF 14A 29 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$5.0M

÷

Cash burned over the last 12 months

$20.8M

What Traws Pharma told the SEC

…and 2022 contained an explanatory paragraph which noted that the Company has suffered recurring losses from operations and there was substantial doubt as to the Company’s ability to continue as a going concern. During the fiscal years ended December 31, 2023, and 2022, and the subsequent interim period through May 17, 2024, there were: (i) no “disagreements” within the meaning of Item…

Traws Pharma, Inc., Form DEF 14A, filed 29 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 80.3% share-count increase The company issued stock. Each share now owns 44.5% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 59% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt